Business
Erasca Reports First Quarter 2026 Business Updates and Financial Results
Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026 Robust balance sheet with cash, cash equivalents, and marketable securities of $409 million as of March 31, 2026 expected to fund o
About this update from Erasca, Inc.
[{"type":"image","alt":"Erasca, Inc.","displaySize":"","headline":null,"caption":"Erasca, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":49,"url":"https://media.zenfs.com/en/globenewswire.com/0b48dd84fa0cc496a6fda02f84d9b85c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/sKuLSdAV0vQhEZPku0Kxnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY5/https://media.zenfs.com/en/globenewswire.com/0b48dd84fa0cc496a6fda02f84d9b85c","width":300,"height":49},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/sKuLSdAV0vQhEZPku0Kxnw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTY5/https://media.zenfs.com/en/globenewswire.com/0b48dd84fa0cc496a6fda02f84d9b85c","width":300,"height":49}},"lazy":false},{"type":"text","content":"Robust monotherapy efficacy and generally well-tolerated safety results observed during dose escalation for ERAS-0015 in both KRAS G12X NSCLC and PDAC reinforce best-in-class potential across RAS-targeted agents","length":211,"tagName":"p"},{"type":"text","content":"ERAS-0015 monotherapy expansion and combination dose escalation data expected in H1 2027; ERAS-4001 Phase 1 preliminary monotherapy data expected in H2 2026","length":156,"tagName":"p"},{"type":"text","content":"Robust balance sheet with cash, cash equivalents, and marketable securities of $409 million as of March 31, 2026 expected to fund operations into H2 2028","length":153,"tagName":"p"},{"type":"text","content":"SAN DIEGO, May 11, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today provided business updates and reported financial results for the fiscal quarter ended March 31, 2026.","length":352,"tagName":"p"},{"type":"text","content":"“We continue to execute well across our RAS-targeting franchise, advancing ERAS-0015 clinical development ahead of schedule,” said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. “The best-in-class potential of ERAS-0015 is striking, highlighted by robust responses in patients with KRAS G12X lung or pancreatic cancer, along with favorable safety and tolerability results primarily consisting of low-grade adverse events in our recently reported data. Notably, we believe ERAS-0015 has the potential to become a backbone of combination ...